Stryker (NYSE:SYK) VP Robert Fletcher Sells 4,544 Shares

Stryker Corporation (NYSE:SYK) VP Robert Fletcher sold 4,544 shares of the stock in a transaction that occurred on Thursday, May 28th. The shares were sold at an average price of $306.87, for a total value of $1,394,417.28. Following the transaction, the vice president directly owned 10,582 shares of the company’s stock, valued at approximately $3,247,298.34. The trade was a 30.04% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Stryker Price Performance

Shares of Stryker stock opened at $305.73 on Friday. The stock has a 50 day moving average of $321.82 and a 200 day moving average of $348.15. Stryker Corporation has a 12 month low of $281.00 and a 12 month high of $404.87. The firm has a market cap of $117.21 billion, a PE ratio of 35.39, a PEG ratio of 1.94 and a beta of 0.80. The company has a current ratio of 2.11, a quick ratio of 1.25 and a debt-to-equity ratio of 0.62.

Stryker (NYSE:SYK) last announced its quarterly earnings results on Thursday, April 30th. The medical technology company reported $2.60 EPS for the quarter, missing analysts’ consensus estimates of $2.98 by ($0.38). Stryker had a net margin of 13.20% and a return on equity of 23.42%. The firm had revenue of $6.02 billion for the quarter, compared to the consensus estimate of $6.34 billion. During the same period in the previous year, the company posted $2.84 earnings per share. Stryker’s quarterly revenue was up 2.6% on a year-over-year basis. Stryker has set its FY 2026 guidance at 14.900-15.100 EPS. On average, research analysts expect that Stryker Corporation will post 14.98 EPS for the current fiscal year.

Stryker Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Tuesday, June 30th will be given a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a dividend yield of 1.2%. The ex-dividend date is Tuesday, June 30th. Stryker’s dividend payout ratio is currently 40.74%.

Institutional Investors Weigh In On Stryker

A number of institutional investors and hedge funds have recently modified their holdings of SYK. Norges Bank bought a new stake in shares of Stryker during the 4th quarter worth approximately $1,822,272,000. Auto Owners Insurance Co lifted its stake in shares of Stryker by 35,047.0% during the 4th quarter. Auto Owners Insurance Co now owns 2,914,741 shares of the medical technology company’s stock worth $1,024,444,000 after acquiring an additional 2,906,448 shares during the last quarter. Wellington Management Group LLP lifted its stake in shares of Stryker by 22.6% during the 4th quarter. Wellington Management Group LLP now owns 6,493,276 shares of the medical technology company’s stock worth $2,282,192,000 after acquiring an additional 1,198,665 shares during the last quarter. Corient Private Wealth LLC lifted its stake in shares of Stryker by 104.4% during the 2nd quarter. Corient Private Wealth LLC now owns 2,245,841 shares of the medical technology company’s stock worth $887,525,000 after acquiring an additional 1,146,998 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership lifted its stake in shares of Stryker by 241.9% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 1,555,638 shares of the medical technology company’s stock worth $511,167,000 after acquiring an additional 1,100,673 shares during the last quarter. 77.09% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

SYK has been the topic of several recent research reports. Deutsche Bank Aktiengesellschaft set a $315.00 target price on shares of Stryker in a research report on Friday, May 1st. Citigroup lowered their price objective on Stryker from $420.00 to $385.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Needham & Company LLC lowered their price objective on Stryker from $454.00 to $418.00 and set a “buy” rating for the company in a research note on Friday, May 1st. Leerink Partners assumed coverage on Stryker in a research note on Monday, April 13th. They issued an “outperform” rating and a $410.00 price objective for the company. Finally, Evercore set a $355.00 price objective on Stryker in a research note on Friday, May 1st. Sixteen analysts have rated the stock with a Buy rating and six have given a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $395.48.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.